The pharmaceutical and biotechnology company Moderna announced today that it is developing two updated vaccines against the Omicron variant of the coronavirus for the fall: one designed against the BA.1 subvariant and another against the BA.4 and BA.5 subvariants.
Vaccine makers including Moderna and Pfizer are developing updated vaccines against Omicron’s rapidly spreading BA.4 and BA.5 subvariants, which have been spreading in the United States in recent weeks.
The bivalent vaccines are designed to target two different variants of the coronavirus: the original one from 2020 and the newer ones brought to the fore by Omicron.
According to Moderna, new clinical data for the mRNA-1273.214 vaccine it is developing against the BA.1 variant showed significantly higher neutralizing antibody responses against the rapidly spreading BA.4 and BA.5 compared to the current booster doses.
The company’s second vaccine, mRNA-1273.222, targets the BA.4/5 strains and is being developed in accordance with recent US Food and Drug Administration (FDA) recommendations.
Source: Capital

Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.